Vitamin D lowered an inflammation marker after colorectal cancer surgery
In patients with low vitamin D levels, supplementation reduced serum IL-6, while changes in other measured inflammatory markers were not statistically significant.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Personalized vitamin D supplementation reduced a blood marker of inflammation in this specific group of patients after colorectal cancer surgery. The abstract does not establish better cancer control, survival, or recovery. Its result concerns a laboratory measurement, and changes in the other measured markers were not statistically significant.
The abstract reports a short trial focused on inflammatory biomarkers. It gives no cancer outcome or adverse-event results, so this abstract-based summary cannot establish clinical benefit or safety.
What researchers found
Serum IL-6
Percentage change with personalized vitamin D supplementation versus placebo after 12 weeks.
What was tested
Researchers enrolled patients with low vitamin D levels and compared supplementation with placebo. Treatment began with a personalized loading dose, then continued at a fixed maintenance dose before the blood markers were measured again.
A selective biomarker result
The clearest result concerned interleukin-6, an inflammation marker. Changes in interferon-gamma and MMP-1 were not statistically significant. That leaves uncertainty about those effects rather than establishing that supplementation cannot affect them.
The original publication
Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial.
Gwenzi T, Weber ANR, Trares K et al.
Br J Cancer · 2026
- PubMed ID
- 41507560
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.